Stock Taper
SCREENER COMPARE ANY 2 STOCKS
REGN
REGENERON PHARMACEUTICALS, INC.
NASDAQ
$794.19
▼ DOWN 1.67% (-13.52)

KEY STATISTICS

Market Cap$81.82 B
52w High$847.00
52w Low$541.00
Dividend Yield0.49%
FrequencyQuarterly
P/E17.40
Volume487.71K
Shares Out.103.02M

COMPANY

LEADERSHIP

Leonard S. Schleifer
CHIEF EXECUTIVE
Leonard S. Schleifer

COMPENSATION 2026

Salary$1,979,922
Stock Awards$0
Incentive Plan Pay$3,682,655
All Other Comp.$1,617,972
Total$7,280,549

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 2, 1991
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
15,410

PRICE TARGET

Target High$1030.00
Target Low$730.00
Target Median$800.00
Target Consensus$820.65

UPCOMING EARNINGS

DateOct 28, 2026
DayWednesday
Rev. Est.$4.54B
OCT
28
WED

PRICE

$794.19 ▼ DOWN 1.67% (−$13.52)
$795$8039:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM794.19

About Regeneron Pharmaceuticals, Inc.

https://www.regeneron.com ↗

Regeneron Pharmaceuticals develops and commercializes medicines for various diseases worldwide, including treatments for eye conditions, atopic dermatitis, cancer, infectious diseases, and more, through collaborations with global partners.

INDUSTRY

Biotechnology

A PRODUCT REGENERON PHARMACEUTICALS, INC. IS KNOWN FOR

Dupixent (dupilumab)
Dupixent (dupilumab)

Dupixent, developed by Regeneron and Sanofi, is a top-selling injectable biologic with $14.15 billion in 2024 global sales, approved for multiple inflammatory conditions and expanding into new indications like eosinophilic esophagitis and COPD.

COMPETITORS

COMPETITOR
ABBV COMPARE
AMGN COMPARE
AZN COMPARE
GSK COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Collaboration Revenue$1.97B $1.97B ▲$1.9B ▼$2.46B ▲
Product$1.59B $1.67B ▲$1.53B ▼$1.64B ▲
Product and Service Other$198.2M $238.6M ▲$171.2M ▼$193.3M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$1.11B $3.27B ▲$941.5M ▼$1.01B ▲
Rest Of World$146.1M $361.4M ▲$152.1M ▼$146.8M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
1,085
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.11% · 3.3M
QQQ
0.36% · 2.2M
XAW.TO
0.07% · 1.3M
SPY
0.12% · 1.2M
JEPI
1.06% · 606.2K
PVAL
2.87% · 528.2K
VIRS
9.15% · 366.0K
RDVY
1.08% · 345.6K
LYPS.DE
0.77% · 311.0K
SCHG
0.31% · 242.4K
DGRW
0.69% · 144.9K
CGGO
0.86% · 128.8K
QQQI
0.36% · 65.3K
TQQQ
0.14% · 62.3K
DFUV
0.28% · 54.1K
XDEE.DE
0.25% · 50.8K
FHLC
1.15% · 49.9K
HMWD.L
0.20% · 45.0K
NUGO
1.37% · 42.6K
BBH
6.75% · 40.2K
QYLD
0.37% · 38.3K
DSTL
1.28% · 33.9K
ZSP.TO
0.12% · 31.1K
NDQ.AX
0.36% · 29.0K
GPIQ
0.40% · 28.0K
AVUS
0.14% · 25.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
55.52%
HOLDERS
1,984
TOP 12 OF 1,984 · RANKED BY POSITION SIZE
Blackrock, Inc.
9.1M sh · $5.68B
Vanguard Group Inc
9.1M sh · $7B
Blackrock Inc.
8.4M sh · $8.88B
Dodge & Cox
4.9M sh · $3.04B
State Street Corp
4.8M sh · $3.01B
Jpmorgan Chase & Co
4.3M sh · $3.23B
Invesco Ltd.
3.9M sh · $2.46B
Franklin Resources Inc
2.8M sh · $1.73B
Geode Capital Management, LLC
2.6M sh · $1.63B
Blackrock Fund Advisors
2.4M sh · $898.49M
Icahn Capital LP
2.4M sh · $109.84K
Fmr LLC
2.3M sh · $1.79B

RATINGS SNAPSHOT

Overall rating: A

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity4
Return On Assets5
Debt To Equity3
Price To Earnings2
Price To Book3
Overall Score4

TRADES BY CONGRESS

HOUSE TRADES
Ro Khanna
Ro Khanna
Purchase
2026-04-13
 Julia Letlow
Julia Letlow
Purchase
2026-02-12
 Gilbert Cisneros
Gilbert Cisneros
Purchase
2025-11-18
 Rob Bresnahan
Rob Bresnahan
Purchase
2025-05-15

INSIDER TRADES

★
OFFICER: EVP GENERAL COUNSEL AND SECRET
LAROSA JOSEPH J
Sale · 12.3K shares
2026-08-19
★
OFFICER: EVP GENERAL COUNSEL AND SECRET
LAROSA JOSEPH J
Purchase · 12.3K shares
2026-08-19
★
OFFICER: EVP GENERAL COUNSEL AND SECRET
LAROSA JOSEPH J
Sale · 9.0K shares
2026-08-19
★
OFFICER: EVP FINANCE CFO
Fenimore Christopher R.
Sale · 4.6K shares
2026-08-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OVERWEIGHT 4
OUTPERFORM 4
NEUTRAL 2
EQUAL WEIGHT 2
SECTOR PERFORM 2
MARKET PERFORM 1
22 GRADES IN THE LAST 12 MONTHS
Leerink Partners MARKET PERFORM Guggenheim BUY Citigroup NEUTRAL Morgan Stanley EQUAL WEIGHT RBC Capital SECTOR PERFORM Cantor Fitzgerald OVERWEIGHT Wells Fargo EQUAL WEIGHT Truist Securities BUY

SECTORS PEERS

PEERPRICE
ELV$394.43COMPARE
CI$278.88COMPARE
ARGX$1023.21COMPARE
COR$322.03COMPARE
IDXX$554.99COMPARE
ZTS$77.34COMPARE
ALNY$237.10COMPARE
INCY$124.37COMPARE